aci-intratumoral-therapies_-_Edited.png

Wednesday, Dec. 2, 2026 | 11a.m.–3 p.m. ET
Live via Zoom Webinar

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of intratumoral therapies, vaccines, & cytokines. FREE for healthcare professionals, students, patients and patient advocates.

Registration Available Soon

Program Organizers

Adi Diab, MD

Adi Diab, MD
Cleveland Clinic

Olivera Finn, PhD

Olivera Finn, PhD
Univeristy of Pittsburgh

Mark Rubinstein, PhD

Mark Rubinstein, PhD
The Ohio State University

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2026 ACI series.

Program Agenda – Coming Soon

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Program Learning Objectives

  • Describe the mechanisms of intratumoral therapies, vaccines, and cytokines.

  • Summarize recent updates in the use of intratumoral therapies, vaccines, and cytokines clinically
    .
  • Outline common toxicities with intratumoral therapies, vaccines and cytokines and their management.

Accreditation Information – Coming Soon

Disclosure of Conflicts of Interest

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

The 2026 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Advanced Practitioner Society for Hematology and Oncology and the Association of Cancer Care Centers.

Partners for Advancing Clinical Education Logo

The 2026 ACI series is jointly provided by Partners for Advancing Clinical Education (Partners) and the Society for Immunotherapy of Cancer.